EU/3/19/2177: Orphan designation for the treatment of glioma

regorafenib

Table of contents

Overview

On 28 June 2019, orphan designation EU/3/19/2177 was granted by the European Commission to Bayer AG, Germany, for regorafenib for the treatment of glioma.

Key facts

Active substance
regorafenib
Intended use
Treatment of glioma
Orphan designation status
Withdrawn
EU designation number
EU/3/19/2177
Date of designation
28/06/2019
Sponsor

Bayer AG
Kaiser-Wilhelm-Allee 1
Wiesdorf
51373 Leverkusen
Tel. +49 30 300139003
E-mail: clinical-trials-contact@bayer.com

Update history

DateUpdate
December 2022The product was withdrawn from the Union Register of orphan medicinal products on request of the Sponsor.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating